Abstract
We describe a patient with cirrhotic liver disease and atrial fibrillation who was treated with spironolactone and digoxin. He was hospitalized because of an incidental finding of a high serum digoxin level (4.2 micrograms/L), but he remained asymptomatic without emerging arrhythmias. Despite discontinuation of both drugs, his serum digoxin level persisted at or above 3.0 micrograms/L for approximately 5 weeks, drawing into question the accuracy of the digoxin assay. Additional digoxin methods gave lower, discrepant results, providing evidence of an assay interference, and several possible sources of digoxin false positivity were evaluated. This included assessment of the contribution of digoxin-like immunoreactive factor (DLIF), digoxin metabolites, and spironolactone. Because the routine digoxin assay used a monoclonal antibody, we also tested for another hypothetical interference: human heterophilic ("anti-mouse") antibodies. We found no contribution from DLIF, digoxin antibodies, or spironolactone to the apparent digoxin results. However, the use of protein A to complex and selectively remove immunoglobulin G molecules markedly lowered the apparent digoxin value, as did the less specific process of ultrafiltration. These re...Continue Reading
References
Oct 6, 1979·Lancet·G HedenborgA Carlström
Jun 4, 1992·The American Journal of Cardiology·R A Kelly, T W Smith
Oct 1, 1991·American Journal of Hypertension·S NaomiN K Hollenberg
Apr 1, 1990·Archives of Internal Medicine·J K GhaliE Ford
Nov 1, 1989·Clinical Science·S W GravesW P Peters
Jan 1, 1986·Critical Reviews in Clinical Laboratory Sciences·S W Graves
Jan 1, 1987·Annual Review of Medicine·S W Graves, G H Williams
Jan 1, 1987·Reviews on Drug Metabolism and Drug Interactions·H W Overdiek, F W Merkus
Apr 30, 1985·Clinica Chimica Acta; International Journal of Clinical Chemistry·J L BockB Wenz
Jun 1, 1985·The Journal of Clinical Endocrinology and Metabolism·R Valdes, S W Graves
Nov 27, 1969·The New England Journal of Medicine·T W SmithE Haber
Jan 1, 1981·Journal of Immunological Methods·D Pain, A Surolia
Nov 1, 1983·Annals of Internal Medicine·S W GravesR Valdes
Jan 1, 1984·Clinical Pharmacology and Therapeutics·M H GaultM A Dawe
Jul 1, 1993·The New England Journal of Medicine·M PackerM K Jolly
Jul 1, 1993·The New England Journal of Medicine·T W Smith
Citations
Sep 25, 2004·Clinical Chemistry and Laboratory Medicine : CCLM·Bogdan Solnica
Mar 2, 2010·Clinical Chemistry and Laboratory Medicine : CCLM·Elena Llorente FernándezJordi To-Figueras
Feb 21, 2006·Clinical Endocrinology·Alison M Jones, John W Honour
Jun 24, 2000·Journal of Toxicology. Clinical Toxicology·M IngelsR F Clark
Aug 5, 2000·Journal of Molecular Biology·W J BallM N Margolies
Nov 27, 2008·The Annals of Pharmacotherapy·Terry E Jones, Raymond G Morris
Nov 7, 2001·The Journal of Urology·B R Morgan, T H Tarter
Jun 16, 2001·Journal of Endocrinological Investigation·M TommasiM Mannelli
Aug 1, 2012·Therapeutic Drug Monitoring·Amitava Dasgupta
Oct 9, 2002·Clinica Chimica Acta; International Journal of Clinical Chemistry·Stanley S Levinson, James J Miller
Dec 10, 1999·Annals of Clinical Biochemistry·C Selby
Sep 30, 2010·Clinical Biochemistry·Esperanza F Hermida-CadahíaJ Carlos Tutor